◆英語タイトル:Kuros Biosciences Ltd (KURN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014382
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月22日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スイス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Kuros Biosciences Ltd (Kuros Biosciences) is a biotechnology company that develops products for tissue repair and regeneration. It develops a family of bone healing products to address indications in trauma and spine called orthobiologics. It is focused on bone repair for trauma, specifically fracture repair, as well as on spinal fusion. Its pipeline of products includes MagnetOs Granules, MagnetOs Putty, KUR-111, KUR-113 and KUR-112. Kuros Biosciences uses a synthetic matrix technology with reliable and pressure resistant, rapid closure of the damaged tissues. The company’s lead sealant product is Neuroseal (KUR-023) developed as an adjunct to suturing for sealing of the dura after cranial surgery. Kuros Biosciences is headquartered in Schlieren, Switzerland.
Kuros Biosciences Ltd (KURN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Kuros Biosciences Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Kuros Biosurgery Raises Additional USD5 Million Financing 11
Kuros Biosurgery Raises USD15.34 Million in Venture Financing 12
Partnerships 13
Cytos Biotech Enters Into Research And Development Agreement With Walter Reed Army Institute 13
Merger 14
Cytos Biotech Merges with Kuros Biosurgery 14
Licensing Agreements 15
Checkmate Pharmaceuticals Enters into Licensing Agreement with Cytos Biotechnology 15
Cytos Biotechnology Enters into License Agreement with Novartis 16
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 17
Equity Offering 18
Kuros Biosciences Raises Funds through Public Offering of Shares 18
Kuros Biosciences Raises Funds through Rights Offering of Shares 19
Cytos Biotechnology Completes Rights Offering Of Shares For US$26.7 Million 20
Cytos Biotechnology Completes Private Placement Of Shares For US$26 Million 21
Cytos Biotechnology Completes Rights Offering Of Shares For US$3.5 Million 23
Debt Offering 25
Cytos Biotechnology Announces Private Placement Of Secured Convertible Notes For US$14.5 Million 25
Kuros Biosciences Ltd – Key Competitors 27
Kuros Biosciences Ltd – Key Employees 28
Kuros Biosciences Ltd – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 30
Financial Announcements 30
Sep 26, 2017: Kuros Biosciences Reports Financial Results for First Half-Year of 2017 30
Apr 26, 2017: Kuros Biosciences Reports Financial Results for 2016 31
Sep 29, 2016: Kuros Biosciences Reports Financial Results for First Half-Year of 2016 33
Apr 26, 2016: Kuros Biosciences Reports Financial Results for 2015 35
Corporate Communications 36
Nov 16, 2017: Kuros announces management changes 36
Apr 28, 2017: Kuros Biosciences Proposes Election of Four New Board Members 37
Apr 13, 2017: Kuros announces CEO succession 38
Other Significant Developments 39
Jan 08, 2016: Cytos Biotechnology will be renamed Kuros Biosciences 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40
List of Tables
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Kuros Biosciences Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Kuros Biosciences Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Kuros Biosciences Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Kuros Biosurgery Raises Additional USD5 Million Financing 11
Kuros Biosurgery Raises USD15.34 Million in Venture Financing 12
Cytos Biotech Enters Into Research And Development Agreement With Walter Reed Army Institute 13
Cytos Biotech Merges with Kuros Biosurgery 14
Checkmate Pharmaceuticals Enters into Licensing Agreement with Cytos Biotechnology 15
Cytos Biotechnology Enters into License Agreement with Novartis 16
Kuros Biosurgery Enters Into Licensing Agreement With Synthes 17
Kuros Biosciences Raises Funds through Public Offering of Shares 18
Kuros Biosciences Raises Funds through Rights Offering of Shares 19
Cytos Biotechnology Completes Rights Offering Of Shares For US$26.7 Million 20
Cytos Biotechnology Completes Private Placement Of Shares For US$26 Million 21
Cytos Biotechnology Completes Rights Offering Of Shares For US$3.5 Million 23
Cytos Biotechnology Announces Private Placement Of Secured Convertible Notes For US$14.5 Million 25
Kuros Biosciences Ltd, Key Competitors 27
Kuros Biosciences Ltd, Key Employees 28
Kuros Biosciences Ltd, Subsidiaries 29